TRIM37 — Tripartite Motif Containing 37

📖 Wiki Page

gene1362 wordssynced 2026-04-02

TRIM37 — Tripartite Motif Containing 37

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TRIM37 — Tripartite Motif Containing 37</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TRIM37</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Tripartite Motif Containing 37</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>17q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td>[4591](https://www.ncbi.nlm.nih.gov/gene/4591)</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>[604193](https://www.omim.org/entry/604193)</td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td>[ENSG00000108395](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108395)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9C0B1](https://www.uniprot.org/uniprot/Q9C0B1)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>964 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~110 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous (brain, heart, liver, lung)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>

...

TRIM37 — Tripartite Motif Containing 37

Overview

Mermaid diagram (expand to render)

TRIM37 (Tripartite Motif Containing 37) is a member of the TRIM (Tripartite Motif) protein family, characterized by the presence of RING finger, B-box, and coiled-coil domains. TRIM37 functions as an E3 ubiquitin ligase, catalyzing the transfer of ubiquitin to specific substrate proteins. The gene is located on chromosome 17q11.2 and encodes a protein of 964 amino acids. [@ncbi_gene]

The TRIM family comprises over 70 members in humans, many of which are involved in diverse cellular processes including protein degradation, signal transduction, and developmental processes. TRIM37 has been studied particularly for its role in peroxisome biogenesis and its involvement in the rare disorder mulibrey nanism (also known as perheentupa syndrome), a condition characterized by growth abnormalities, organomegaly, and various neurological features. [@avela2012]

This page reviews TRIM37's normal biological function, its role in disease, expression patterns, and therapeutic implications.

Normal Biological Function

Structural Features

TRIM37 contains several conserved domains:

| Domain | Position | Function |
|--------|----------|----------|
| RING finger | N-terminal | E3 ubiquitin ligase activity |
| B-box | Central | Protein-protein interactions |
| Coiled-coil | Central | Dimerization/oligomerization |
| SPR domain | C-terminal | Substrate recognition |

The RING finger domain coordinates zinc ions and catalyzes ubiquitin transfer, making TRIM37 an active E3 ubiquitin ligase. The coiled-coil domain mediates protein-protein interactions and allows formation of higher-order complexes.

E3 Ubiquitin Ligase Activity

As an E3 ubiquitin ligase, TRIM37 catalyzes ubiquitination of target proteins:

Ubiquitin activation: E1 enzyme activates ubiquitin

Ubiquitin transfer: E2 enzyme receives activated ubiquitin

Substrate ubiquitination: TRIM37 facilitates ubiquitin transfer to substrate

Polymer formation: Subsequent ubiquitin molecules extend the chain

Ubiquitination can target proteins for degradation, alter their localization, or modulate their activity.

Role in Peroxisome Biogenesis

TRIM37 is essential for peroxisome biogenesis:

Peroxisome assembly: Required for proper peroxisomal membrane formation
Matrix protein import: Involved in importing peroxisomal matrix enzymes
Peroxisome proliferation: Regulates peroxisome number and function

Peroxisomes are essential organelles for fatty acid oxidation, plasmalogen synthesis, and reactive oxygen species metabolism. Their dysfunction affects multiple organ systems, particularly the brain and liver. [@ravenel2021]

Role in Centrosome Function

TRIM37 localizes to the centrosome, the main microtubule-organizing center:

Centrosome maturation: Required for proper centrosome development
Ciliary function: Important for primary cilium formation
Cell division: Involved in spindle pole organization

Defects in centrosome function can lead to developmental abnormalities and impaired neurogenesis. [@kim2021]

Disease Associations

Mulibrey Nanism

Mulibrey nanism (MUL) is a rare autosomal recessive disorder caused by mutations in TRIM37. The name derives from the key features: MUskular weakness, LIver abnormalities, BRachycephaly, and EYe abnormalities. [@avela2012]

Clinical Features

Patients with mulibrey nanism present with:

Growth failure: Prenatal and postnatal growth retardation
Brachycephaly: Abnormal head shape
Muscle weakness: Hypotonia and motor delays
Liver involvement: Hepatomegaly and elevated liver enzymes
Ocular abnormalities: Various visual disturbances
Cardiac defects: Sometimes associated with cardiomyopathy

Molecular Basis

Over 30 pathogenic variants in TRIM37 have been identified, including:

Nonsense mutations: Create premature stop codons
Missense mutations: Alter protein function
Splice site mutations: Cause aberrant splicing
Deletions: Remove portions of the gene

Most mutations result in loss of TRIM37 function, reducing E3 ubiquitin ligase activity.

Neurological Involvement

While mulibrey nanism is primarily a developmental disorder, neurological features include:

Developmental delay: Variable intellectual disability
Motor impairment: Delayed walking and coordination problems
Seizures: Some patients experience epileptic episodes
Movement disorders: Rare cases of choreoathetosis

The neurological involvement likely reflects both peroxisomal dysfunction and abnormal brain development.

Cancer Predisposition

TRIM37 dysfunction may increase cancer risk:

Somatic mutations: Found in some cancers
Deregulated ubiquitination: May affect tumor suppressors
Genomic instability: Centrosome defects promote aneuploidy

Expression Patterns

Tissue Distribution

TRIM37 is expressed in most human tissues:

Brain: Throughout the brain, with higher expression in certain regions
Liver: High expression in hepatocytes
Heart: Moderate expression in cardiac muscle
Lung: Bronchial epithelial cells
Kidney: Tubular cells
Muscle: Skeletal muscle fibers

Cellular Localization

Within cells, TRIM37 localizes to:

Cytoplasm: Diffuse cytoplasmic distribution
Peroxisomes: Peroxisomal membrane association
Centrosomes: Centrosomal localization
Nucleus: Some nuclear localization observed

Pathogenesis Mechanisms

Peroxisome Dysfunction

TRIM37 deficiency causes peroxisomal abnormalities:

Reduced peroxisome number: Fewer functional peroxisomes

Impaired matrix import: Decreased peroxisomal enzyme levels

Accumulation of substrates: Elevated very-long-chain fatty acids

Membrane defects: Abnormal peroxisomal membranes

Peroxisomal dysfunction particularly affects lipid metabolism and can cause secondary mitochondrial dysfunction. [@uchida2019]

Ubiquitination Defects

Loss of TRIM37-mediated ubiquitination affects:

Protein quality control: Reduced degradation of damaged proteins
Signaling pathways: Altered signal transduction
Organelle function: Impaired peroxisome and centrosome function

Cellular Stress

TRIM37 deficiency creates cellular stress:

Oxidative stress: Elevated reactive oxygen species
ER stress: Accumulation of misfolded proteins
Metabolic stress: Impaired lipid metabolism

Therapeutic Approaches

Current Management

No cure exists for TRIM37-related disorders. Management includes:

Growth monitoring: Regular height and weight tracking
Liver function tests: Monitor hepatic involvement
Ophthalmologic evaluation: Regular eye exams
Cardiac evaluation: Echocardiograms as needed
Developmental support: Early intervention programs

Therapeutic Strategies

Emerging approaches include:

1. Gene Therapy

Viral vector delivery: Deliver functional TRIM37
mRNA therapy: Transient TRIM37 expression
Gene editing: CRISPR-based approaches

2. Protein Replacement

Recombinant protein: Purified TRIM37 protein
Enzyme enhancement: Boost peroxisomal function

3. Small Molecule Approaches

Peroxisome inducers: Increase peroxisome biogenesis
Antioxidants: Reduce oxidative stress
Metabolic modulators: Support cellular energetics

Animal Models

Mouse Models

TRIM37 knockout mice have been generated:

Growth retardation: Similar to human phenotype
Peroxisomal defects: Reduced peroxisome function
Neurological abnormalities: Behavioral changes

Zebrafish Models

Zebrafish studies reveal:

Developmental defects in trim37 morphants
Peroxisome abnormalities
Brain development issues

Research Directions

Key Questions

Substrate identification: What proteins does TRIM37 ubiquitinate?

Mechanism elucidation: How does TRIM37 regulate peroxisome biogenesis?

Therapeutic targets: Can peroxisome function be restored?

Genotype-phenotype: What determines disease severity?

Future Research

Priority areas include:

Proteomics: Identify TRIM37 substrates
Structural studies: Understand enzyme mechanism
Clinical trials: Develop outcome measures
Natural history: Document disease progression

Summary

TRIM37 is an E3 ubiquitin ligase critical for peroxisome biogenesis and centrosome function. Mutations cause mulibrey nanism, a rare disorder characterized by growth failure, organomegaly, and various neurological features. The disease mechanism involves loss of TRIM37 function, leading to peroxisomal dysfunction and cellular stress.

Current management focuses on symptomatic treatment, but emerging therapies including gene therapy and small molecule approaches offer hope for disease modification. Further research into TRIM37 substrates and mechanisms will guide therapeutic development.

References

[NCBI Gene: TRIM37](https://www.ncbi.nlm.nih.gov/gene/4591). NCBI, 2024.

[UniProt: TRIM37 (Q9C0B1)](https://www.uniprot.org/uniprot/Q9C0B1). UniProt, 2024.

[Avela et al., TRIM37 and mulibrey nanism (2012)](https://pubmed.ncbi.nlm.nih.gov/22337755/). J Med Genet, 2012.

[Hatakeyama et al., TRIM proteins in neurodegeneration (2017)](https://pubmed.ncbi.nlm.nih.gov/28425926/). J Mol Neurosci, 2017.

[Ravenel et al., TRIM37 and peroxisome biogenesis (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/). Nat Commun, 2021.

[Kareem et al., TRIM37 mutations and phenotypes (2021)](https://pubmed.ncbi.nlm.nih.gov/34045321/). Hum Mol Genet, 2021.

[Ozon et al., TRIM37 clinical spectrum (2020)](https://pubmed.ncbi.nlm.nih.gov/33252918/). Am J Hum Genet, 2020.

[Uchida et al., Peroxisome deficiency and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31154017/). Biochim Biophys Acta, 2019.

[Kim et al., Centrosome function in neurogenesis (2021)](https://pubmed.ncbi.nlm.nih.gov/34092466/). Trends Cell Biol, 2021.

[Cheng et al., TRIM37-mediated ubiquitination (2019)](https://pubmed.ncbi.nlm.nih.gov/30824118/). Mol Cell, 2019.

[Matsuda et al., E3 ubiquitin ligases in neuronal disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30639289/). Neurobiol Dis, 2019.

[Hildebrandt et al., Peroxisome biogenesis disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31827052/). Nat Rev Dis Primers, 2019.

[Peroxisome Biogenesis Pathway](/mechanisms/peroxisome-biogenesis)
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-pathway)
[Centrosome Function](/mechanisms/centrosome-biology)
[Mulibrey Nanism](/diseases/mulibrey-nanism)
[Peroxisome Disorders](/diseases/peroxisome-disorders)

Pathway Diagram

The following diagram shows the key molecular relationships involving TRIM37 — Tripartite Motif Containing 37 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

TRIM37 — Tripartite Motif Containing 37

TRIM37 — Tripartite Motif Containing 37

TRIM37 — Tripartite Motif Containing 37

TRIM37 — Tripartite Motif Containing 37

Overview

Normal Biological Function

Structural Features

E3 Ubiquitin Ligase Activity

Role in Peroxisome Biogenesis

Role in Centrosome Function

Disease Associations

Mulibrey Nanism

Clinical Features

Molecular Basis

Neurological Involvement

Cancer Predisposition

Expression Patterns

Tissue Distribution

Cellular Localization

Pathogenesis Mechanisms

Peroxisome Dysfunction

Ubiquitination Defects

Cellular Stress

Therapeutic Approaches

Current Management

Therapeutic Strategies

1. Gene Therapy

2. Protein Replacement

3. Small Molecule Approaches

Animal Models

Mouse Models

Zebrafish Models

Research Directions

Key Questions

Future Research

Summary

References

Related Pathways

See Also

Pathway Diagram